The HEMO study - Where do we go from here?

Current Opinion in Nephrology and Hypertension

Volumn 12, Issue 6, 2003, Pages 587-591

  Himmelfarb, Jonathan ^a  

^a MAINE MEDICAL CENTER   (United States)

Author keywords

Adequacy; HEMO; Hemodialysis; Urea; Uremic toxicity

Indexed keywords

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL SIGNIFICANCE;

HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS;

EID: 0442323430     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200311000-00003     Document Type: Review

References (30)

1. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription on patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981; 305:1176-1181
2. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010-2019. This paper presents the primary clinical results from the HEMO trial.
3. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12:2753-2758.
4. Sargent JA, Gotch FA. Mathematic modeling of dialysis therapy. Kidney Int Suppl 1980; Suppl 10:S2-S10.
5. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23:661-669.
6. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994; 23:272-282.
7. Parker TF III, Husni L, Huang W, et al. Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 1994; 23:670-680.
8. Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50:550-556.
9. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3:1227-1237.
10. Woods HF, Nandakumar M. Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 2000; 15 (Suppl 1):36-42.
11. Port FK, Wolfe RA, Hulbert-Shearon TE, et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane: results from the USRDS Dialysis Morbidity and Mortality Study. Am J Kidney Dis 2001; 37:276-286.
12. Locatelli F, Marcelli D, Conte F, et al. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 1999; 55:286-293.
13. Koda Y, Nishi S, Miyazaki S, et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52:1096-1101.
14. Locatelli F. Dose of dialysis, convection and haemodialysis patients outcome - what the HEMO study doesn't tell us: the European viewpoint. Nephrol Dial Transplant 2003; 18:1061-1065.
15. National Institute of Diabetes, Digestive Kidney Diseases. Atlas of end-stage renal disease in the United States. USRDS 2002 Annual Report. 2002. Bethesda, MD: National Institute of Diabetes, Digestive Kidney Diseases; USA.
16. Greene T, Beck GJ, Gassman JJ, et al. Design and statistical issues of the hemodialysis (HEMO) study. Control Clin Trials 2000; 21:502-525. This report presents the rationale and study design for the HEMO trial, including a description of the logistics of the dialysis dose intervention and flux intervention, as well as quality control measures, statistical analyses, and power analysis assumptions.
17. Locatelli F, Hannedouche T, Jacobson S, et al. The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. J Nephrol 1999; 12:85-88.
18. Spiegel DM, Baker PL, Babcock S, et al. Hemodialysis urea rebound: the effect of increasing dialysis efficiency. Am J Kidney Dis 1995; 25:26-29.
19. Pedrini LA, Zereik S, Rasmy S. Causes, kinetics and clinical implications of post-hemodialysis urea rebound. Kidney Int 1988; 34:817-824.
20. Depner T, Beck G, Daugirdas J, et al. Lessons from the Hemodialysis (HEMO) study: an improved measure of the actual hemodialysis dose. Am J Kidney Dis 1999; 33:142-149.
21. urea formula used in the HEMO study.
22. Katzarski KS, Charra B, Luik AJ, et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 1999; 14:369-375.
23. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286-1291. This important study indicates the potential independent effect of dialysis time on dialysis outcomes.
24. Lowrie EG, Li Z, Ofsthun N, Lazarus JM. Body size, dialysis dose and death risk relationships among hemodialysis patients. Kidney Int 2002; 62:1891-1897. This paper describes the independent effect of body size on clinical outcomes, which is separate from dialysis dose.
25. Port FK, Ashby VB, Dhingra RK, et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13:1061-1066.
26. Owen Jr WF, Chertow GM, Lazarus JM, Lowrie EG. Dose of hemodialysis and survival: differences by race and sex. JAMA 1998; 280:1764-1768.
27. Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56:1136-1148.
28. Levin N, Greenwood R. Reflections on the HEMO study: the American viewpoint. Nephrol Dial Transplant 2003; 18:1059-1060.
29. Woods JD, Port FK, Orzol S, et al. Clinical and biochemical correlates of starting 'daily' hemodialysis. Kidney Int 1999; 55:2467-2476.
30. Ward RA, Schmidt B, Hullin J, et al. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000; 11:2344-2350.